**Design, Formulation and Physicochemical Evaluation of Dimenhydrinate Orally Disintegrating Tablets**

Abolfazl Aslani1, Alireza Ghasemi1, Shekofeh Karbasizadeh Esfahani1

1. Department of Pharmaceutics, School of Pharmacy and Novel Drug Delivery Systems Research Center, Isfahan, Iran

Purpose: Design, formulation and physicochemical evaluation of dimenhydrinate 25 mg oral tablets that disintegrate in oral cavity in a proper time. This product is easy to use for babies, geriatrics and people who have difficulty in swallowing.

Methods: 31 formulations were designed in 3 categories via Design-Expert software version 7. Group 1 consist of super-disintegrating bases, group 2 consist of effervescent bases and group 3 consist of super-disintegrating and effervescent bases together. Proposed by Design-Expert software, the optimum formulations were selected in each category and the tablets were produced by direct compression method. Tablets evaluated by friability, thickness, hardness, weight variation, drug content, content uniformity, disintegration time, wetting time, dissolution and moisture uptake tests.

Results: The angle of repose and compressibility index of formulations were in the range of 24.65-29.08 and 5.02-9.01 % respectively. Thickness, hardness, wetting time, friability and content uniformity of formulations were in the range of 3.36-3.84 mm, 33.25-38.03 N, 19-37 seconds, 0.31-0.42 % and 96.44-99.02 % respectively. Disintegration time of the groups 1, 2 and 3 were in the range of 16-70, 47-72 and 12-35 seconds respectively.

Conclusion: Mixture of powders and orally dispersible tablets passed all tests. The results showed that formulations containing both of super-disintegrants and effervescent bases had better disintegration time compare to other formulations.

Key words: Orally disintegrating tablets, Dimenhydrinate, Direct compression, Motion sickness, Meniere's disease

**Introduction**

Oral drug delivery systems have wide admission up to 50-60% of total solid dosage forms. Solid dosage forms are favorite because of simplicity of administration, exact dosage, self-medication, pain avoidance and significantly the patient compliance (1). Low disintegration time of tablet results in fast dissolution and speedy absorption which prepare rapid onset of clinical outcome (2). Pre-gastric absorption of drugs from mouth may be illustration improved oral bioavailability (3). Geriatric patients may find the administration of the traditional oral dosage forms hard as they regularly require medicines to retain a healthy life. Children may also have problem in absorbency because of their nervous systems and underdeveloped muscular. The problem of devouring tablets is also apparent in journey patients who may not have ready access to water. Above-mentioned problem can be resolved by means of orally disintegrating tablets (ODTs) (4). Over a decade, the request for expansion of ODTs has enormously improved as it has important impact on the patient compliance. ODTs suggest an advantage for patients who have problem in consuming. It has been reported that dysphagia is usual among all age groups and particular with pediatric, geriatric population along with institutionalized patients and patients with vomiting, nausea and motion sickness complications. ODTs with good taste and flavor improve the tolerability of bitter drugs by different groups of population. ODTs are also named as orodispersible tablets, quick disintegrating tablets, fast disintegrating tablets, mouth dissolving tablets, fast dissolving tablets, rapid dissolving tablets and porous tablets (5). However, of all the above idioms, United States pharmacopoeia (USP) confirmed these dosage forms as ODTs. Currently, European Pharmacopoeia has used the idiom orodispersible tablet for tablets that disperses readily and within 3 min in mouth before swallowing. United States Food and Drug Administration (US FDA) has been described ODTs by “A solid dosage form containing medicinal substance or active ingredient which disintegrates rapidly usually within a matter of seconds when placed upon the tongue”. The disintegration time for ODTs commonly confines from several seconds to about a minute (6, 7).

Dimenhydrinate is a salt of diphenhydramine and 8-chlorotheophyline. Dimenhydrinate affect the body by antihistaminic and anticholinergic properties. Diphenhydramine has antagonistic influence on H1 receptor for inhibition and treating of nausea, vomiting, motion sickness and Meniere's disease. Meniere's disease is a persistent sickness that affects a considerable number of patients every year in the world. The disease is distinguished by periodic episodes of vertigo lasting from minutes to hours, with undulating intuitive hearing loss, tinnitus, and aural pressure. Although there is no cure at the moment, more than 85% of patients involve with Meniere's disease are relieved by medicinal treatment like dimenhydrinate. Drowsiness of diphenhydramine is neutralized by 8-chlorotheophylline. Dimenhydrinate is applied as an over-the-counter (OTC) and self-medication drug. Nausea and vomiting in order to motivating chemoreceptor trigger zone (CTZ) is treated by dimenhydrinate 5–12.5 mg for pediatric patients and 50-100 mg for adults at least 30 min before the journey every 6 hours are suitable dosage of dimenhydrinate. This dose may be repeated every 4h if required, but a total daily dose of 300 mg should not be exceeded (8, 9).

The effect of debilitating central nervous system and cause sedation, drowsiness, confusion and lack of coordination. Antimuscarinic properties, such as atropine can cause side effects, including dry mouth, decreased secretion of the respiratory tract, urinary retention, decreased gastrointestinal motility and constipation are dimenhydrinate side effects (10).

Dimenhydrinate is instable in gastrointestinal pH, by oral administration the absorption of the drug is variable and undergoes widespread first pass metabolism, after oral administration, bioavailability is 46% (9).

Dimenhydrinate's dosage forms in the world pharmaceutical market has capsules 50 mg, chewable tablets 50 mg, syrups 5 mg/2 ml and 3 mg /ml, injectable 50 mg/ml and Suppositories 25, 50 and 100 mg (11).

The goal of this study was to design, formulate and evaluate the physiochemical properties of dimenhydrinate 25 mg ODTs in order to decrease disintegration time in oral cavity as well as providing patient convenience, particularly for people with swallowing difficulties. By using super-disintegrants and effervescent bases improve water uptake with minimum wetting time and accordingly reduce the disintegration time.

**Materials and Methods**

**Materials**

The materials used in the formulations with their manufacture/sources of ingredients were as follows: Dimenhydrinate was obtained from Tehran Daru Pharmaceutical Company (Tehran, Iran). Sodium starch glycolate (SSG), cross carmellose sodium (CCS), coss povidone (CP), microcrystalline cellulose and also flavoring agents such as cherry and tutti-frutti were provided by Farabi Pharmaceutical Company (Isfahan, Iran). Citric acid anhydrous, Na bicarbonate, menthol, mannitol, Mg stearate and polyethylene glycol 6000 (PEG 6000) were purchased from Merck (Germany) and sucralose was supplied by Kamvar company (Isfahan, Iran).

**Spectrophotometric Analysis**

**Determination of dimenhydrinate λmax in phosphate buffer pH 6.8 and purified water**

For determination of dimenhydrinate λmax in phosphate buffer and purified water, absorbancies of standard solution were measured in the wavelengths of 200, 210, 220, 230, 240, 250 … and 400 nm using 1cm quartz cell.

**Determination of dimenhydrinate standard curve in phosphate buffer pH 6.8**

10 mg of dimenhydrinate powder transfer into 250 ml volumetric flask and diluted by phosphate buffer pH 6.8. By transferring 0.31, 0.62, 1.25, 2.5, 5 and 10 ml from this solution into a series of 25 ml of volumetric flasks and diluted by phosphate buffer pH 6.8 to prepare the concentrations of 0.5, 1, 2, 4, 8 and 16 μg/ml, respectively. Absorbancies of these solutions measured at λmaxin phosphate buffer pH 6.8 and this method was taken 3 times per day for 3 following days.

**Determination of dimenhydrinate standard curve in purified water**

10 mg of dimenhydrinate powder transfer into 250 ml volumetric flask and diluted by purified water. By transferring 0.31, 0.62, 1.25, 2.5, 5 and 10 ml from this solution into a series of 25 ml of volumetric flasks and diluted by purified water to prepare the concentrations of 0.5, 1, 2, 4, 8 and 16 μg/ml, respectively. Absorbance of all solutions measured at λmax in purified water and this method was taken 3 times per day for 3 following days.

**Evaluation of powder mixture**

The angle of repose, compressibility index and Hausner's ratio are the main flowability properties of mixed powders.

**Angle of repose (θ)**

Angle of repose is the internal angle between the surface of the mass of blend and the horizontal surface. By passing the blend through a funnel permanent to a burette foundation at a special height (4 cm) the angle of repose was known. The radius and height of the mass was measured. Angle of repose was calculated by using the formula (12):

θ = tan -1 (h / r) Eqn. 1

h = Height of the mass

r = Radius of the mass

**Compressibility index**

It is a plain test to appraise $ρt $and $ρb $of a powder and the level at which it packed down. The compressibility index formula is as (13):

Compressibility index (%) = [($ρt$–$ρb$) /$ρt$] \* 100 Eqn. 2

$ρ$b = weight of the powder / volume of the packing Eqn. 3

$ρt$ = weight of the powder / tapped volume of the packing Eqn. 4

**Hausner's ratio**

It shows the flow physical characteristics of the powder. The ratio between tapped density to the bulk density of the powders is named Hausner's ratio (13):

Hausner's ratio = $ρ$Tapped / $ρ$Bulk Eqn. 5

**Experimental design**

The product variables that affects product quality was investigated by Box-Behnken in Design-Expert version7 (DX7) software. Using the selected independent variable, a Box-Behnken design study was planned and the effect on dependent variable was measured. Based on relationship between dependent and independent variables, optimum formula was determined. The ODTs were designed in 3 groups. First group was designed applying super-disintegrating materials with 3 independent and 2 dependent variables. Factor A was sodium starch glycolate (SSG) in three levels (3, 7.5 and 12 mg), factor B was cross carmellose (CCS) in three levels (3.5, 5.25 and 7 mg) and factor C was cross povidone (CP) in three levels (3, 5.25 and 7.5 mg). Second level was designed applying effervescent materials with 2 independent and 2 dependent variables. Factor A was citric acid anhydrous in three levels (9, 18 and 27 mg) and factor B was Na bicarbonate in three levels (13, 24 and 35 mg). The effervescent components and the ratios between them were specified the neutralization of acids and alkali and the admissible amount of each component. Third group was designed applying effervescent and super-disintegrating materials with 2 independent and 2 dependent variables. Factor A was citric acid anhydrous in three levels (12, 24 and 36 mg) and factor B was cross povidone in three levels (4, 7 and 10 mg) (Tables 1-3). The weight of tablets in group 1 and 2 was 150 mg and in group 3 was 200 mg. Ratios between effervescent components were specified according to neutralization of acid and alkali. In this study, designed by DX7 software, 2 dependent variable has been analyzed as answer; disintegration time and friability test of prepared ODTs.

**Preparation of tablets**

All ingredients from every formulation were weighed separately. Manitol, avicel, super-disintegrating or effervescent materials were mixed for 5 minutes, flavoring agent and sucralose were added afterwards to the blend and mixed. Finally, the lubricant agent (Mg stearate or PEG 6000) was added and then mixed for 5 minutes again. The tablets were compressed and the weight of tablets were determined as 150 mg and 200 mg (Tables 4-6). Round flat-shaped tablets were produced using die and punch 8 mm (Kilian & Co, Germany).

**Physicochemical evaluation of the prepared tablets:**

**Weight variation**

Randomly, 20 tablets were chosen after compression and the average weight was determined. None of the tablets deviated from the mean weight by more than ±7.5 % (13, 14).

**Friability test**

Friability test was accomplished to determine the effects of shock and friction. 10 tablets were weighed and put in the friabilator machine (Erweka, TAP, Germany) and regulated on the speed of 25 rpm for 4 minutes. The separated particles of the tablets were removed cautiously and tablets were reweighed. Compressed tab­lets should not decrease more than 1% of weight. Friability percentage was calculated by following equation (15).

$Friability(\%)=\frac{primary weight of the tablets –terminal weight of the tablets}{primary weight of the tablets}$×100 Eqn. 6

**Thickness test**

This test was determined for 20 tablets of each formulation using a Vernier caliper and the mean thickness was determined in mm. The variation limit of thickness should be controlled within a ±5% of a standard (12).

**Hardness test**

In this study, ten tablets were chosen randomly and individually located in a hardness tester (Erweka, 24-TB, Germany) and then the hardness of tablets described in Newton. Hardness in the ODTs was usually less than conventional tablets (16).

**Assay**

Twenty ODTs were weighed and powdered. The powder equivalent to 25 mg dimenhydrinate was weighed accurately and dissolved in 25 ml of phosphate buffer pH 6.8. The solution was shake excellently. By filtration through Whatmann No.41 filter paper the undissolved materials was eliminated. Then the serial dilutions were prepared. The absorbance of diluted solutions measured at λmax in phosphate buffer pH 6.8. The concentration of the drug was calculated from the standard curve of the dimenhydrinate in phosphate buffer pH 6.8 (17).

**Content uniformity**

Ten tablets of each formulation were weighed and powdered. Al­iquot of this powder containing 25mg of dimenhydrinate was accurately weighed, added 50 ml of phosphate buffer pH 6.8 and shaken for 15 minutes. Final volume was regulated to 100 ml with phosphate buffer pH 6.8 and filtered (Whatman No.1 filter paper). From this solution, 10 ml was diluted to 100 ml. 2 ml of this solution di­luted to 10 ml with phosphate buffer pH 6.8 to made final solution. Absorbance of this solution was noted at λmax in phosphate buffer pH 6.8 using UV/Vis spectrophotometer against a blank and the results was compared from a calibration curve prepared with standard dimenhydrinate in the similar medium (18).

**In-vitro disintegration time**

The test was done on six tablets using the fixed basket containing six cylindrical glass tubes, stainless steel basket with certain mesh is the bottom of each tube. Six tablets of every formulation were used to calculate disintegration time. Purified water was disintegration medium and temperature was maintained 37±2°C. Disintegration time of six tablets was determined (19).

**Wetting time**

A part of twice-folded tissue paper was put in a small petri dish (internal diameter of 5.5 cm) containing 6 ml of purified water. A tablet was located on the paper and the time required for ending wetting time was computed (20).

**In-vitro dissolution studies**

Dissolution testing of dimenhydrinate ODTs was done with paddle method in USP dissolution apparatus at 50 rpm and temperature 37±0.5°C in purified water (13). 5 ml sample was eliminated and replaced by purified water at times of 1, 2, 3, 4, 5 and 6 minutes to determine the concentration by UV spectroscopy method at λmax in purified water.

**Taste evaluation of the prepared tablets**

To assessment the taste, by Latin-square method, the panel tests were done. At first, several flavoring agents such as, menthol, tutti-frutti, cherry and without flavor were prepared for formulations but the amount of excipients, sweeteners and active ingredient were fixed. 20 healthy volunteers were selected and separated into four categories: group one was given cherry and menthol (A), tutti-frutti and menthol (B), menthol (C) and without flavoring agents (D). The group two: B, C, D and A, group three: C, D, A and B and the group four was the D, A, B and C. Then, the volunteers were inquired to score each of the formulation from 1 to 5 (1: bad, 2: poor, 3: average, 4: good, 5: very good taste) (21).

**Moisture uptake study**

ODTs usually have high concentration of hydrophilic excipients with the minimum possible hardness which together contributes to their increased capacity to moisture uptake. Moisture uptake studies for ODTs should be steered into the stability of the formulation; thus, moisture uptake study is a significant phase in the case of ODTs. Moisture uptake studies was done by weight design. Ten tablets were put in the desiccators over calcium chloride at 37°C for 24 hours to certify that all tablets were dried completely. The tablets were weighed and exposed to 75% RH at room temperature for 14 days. The required humidity can be attained by keeping saturated sodium chloride solution at the underneath of the desiccators for 3 days. The tablets were weighed again and the percent increase in weight was recorded (22, 23).

**Results**

The λmax of dimenhydrinate solution in phosphate buffer pH 6.8 was 279 nm. The standard curve of dimenhydrinate in phosphate buffer pH 6.8 was determined spectrophotometrically by curve equation y= 0.0443x + 0.003 and the regression was R² = 0.999.

The λmax of dimenhydrinate solution in purified water was 276 nm. The standard curve of dimenhydrinate in purified water was determined spectrophotometrically by curve equation y= 0.0322x + 0.005 and the regression was R² =0.999.

Designed formulations by Design-Expert software elucidated in Tables 1-3. The formulation mixed powders was characterized via different tests such as bulk density, tapped density, angle of repose, Husner's ratio and compressibility index (Table 8). Selected formulations of groups 1(OS), 2(OE) and 3(OSE) were analyzed by different tests such as thickness, hardness, weight variation, friability, disintegration time, assay, content uniformity, wetting time and water content (Table 9). Design-Expert software proposed one optimum formulation for each group (Table 7). Analyzed tests for optimum mixed powder and ODTs were done (Tables 8, 9). Weight of 20 tablets in groups 1 and 2 were in range of 146 mg to 152 mg and 147 mg to 151 mg, respectively; and in group 3 was in range of 195 mg to 203 mg. Friability, thickness and hardness of optimum formulations of groups 1, 2 and 3 were 0.31-0.42%, 3.36-3.84 mm, 33.25-38.03 N respectively.

Wetting time, that facilitates faster dispersion in oral cavity, was in range of 19-37 sec. Drug content of optimum formulations was in range of 96.44-99.02 %. The in-vitro disintegration time of groups 1, 2 and 3 were in range of 16-70 seconds, 47-72 seconds and 12-35 seconds, respectively. Results of in-vitro dissolution are shown in Figure 1. Moisture uptake studies showed that results were in range of 0.15-0.55 at 75 % RH. ODTs with combination of tutti-frutti and menthol flavoring has given the best score by volunteers.

**Discussion**

Dimenhydrinate is mostly used to treat [nausea](https://en.wikipedia.org/wiki/Nausea), [vomiting](https://en.wikipedia.org/wiki/Vomiting) and [dizziness](https://en.wikipedia.org/wiki/Dizziness) caused by motion sickness. Dimenhydrinate has also been found to help in the treatment of ear congestion. Dimenhydrinate’s ODT is useful for peoples with problem in swallowing and don’t access to water. ODTs have pre-gastric absorption and help to by-passing the hepatic first pass effect.

Formulations with disintegration time over 60 sec and friability out of range 20% to 40% were ignored by Design-Expert. Standard curve of dimenhydrinate in phosphate buffer pH 6.8 and purified water was plotted by UV spectrophotometry to analyzing assay test, content uniformity and in-vitro dissolution test. By Design-Expert software, all formulations were designed, F1-F13 formulations (group 1) were designed with different amount of SSG, CCS, and CP, F14-F22 formulations (group 2) were designed with different amount of citric acid and Na bicarbonate and F23-F32 formulations (group 3) were designed with different amount of citric acid and cross povidone. By neutralization of acid and alkali, the effervescent components and ratios between them were determined.

Tablets with disintegration time over 60 seconds were ignored. Design-Expert program proposed optimum formulation for each group. Formulations with less disintegration time and friability between 0.30-0.40 % were selected. After calculating error percentage, OS (optimum formulation of group 1), OE (optimum formulation of group 2) and OSE (optimum formulation of group 3) were chosen as final formulations for every group (table 7).

One of important factor that affect on powder flow is angle of repose. In this study angle of repose was in the range of 24.65 to 29.08. According to USP, all formulations had superfine flow for compression and so tablets were prepared. In other study on zolmitriptan ODTs angle of repose was in the range of 22.32 to 48.42 (12), which confirm our results.

Hardness of conventional tablets are more than ODTs. In this study hardness of tablets was in the range of 33.25 to 38.03 N. In other studies on ondansetron, metoclopramide and rizatriptan ODTs, hardness was in the range of 20-40 N (24-26), which confirm our results.

Friability in 3 groups was less than 1% and in range of 0.31-0.42%. In other study on piroxicam ODTs friability was in the range of 0.33-0.66%, (27) that confirm our results. Friability and hardness results showed that all tablets had proper mechanical strength.

According to USP, for tablets which their weight are between 130-324 mg, only two tablets can be out of range of ±7.5% of weight (for tablets 150 mg weight ±11.25 and for tablets 200mg weight ±15 mg) (13). In groups 1 and 2, weight of tablets were in the range of 150 ±11.25 mg; and in group 3 tablets weight were in the range of 200 ±15 mg.

Content uniformity test was done to determine the true dosage of each tablet. The range of content uniformity were within 85-115% limitation specified in the USP 38-NF 33 for dimenhydrinate tablets, in this study content uniformity were between 96.44-99.02%, elucidating that the powders were mixed well before compression. All tablets were in the range.

Assay test was in range of 24.86-25.06 mg. Assay of all formulations was in the range mentioned in USP (13).

The most important test for preparation of ODTs is disintegration time test. Shorter disintegration time is better for admission by patients. In groups 1, 2 and 3, disintegration time was in the range of 16-75 seconds, 47-77 seconds and 12-35 seconds, respectively. The formulations with combination of super-disintegrating with effervescent bases were better than formulations with only super-disintegrating and only effervescent bases. In other studies, disintegration time was in the range of 9-72 seconds (24-26).

The range of wetting time was 19-37 seconds. In other studies wetting time has been reported between 9-75 seconds. The results of other studies, with super-disintegrant bases only, confirm our results (24, 25, 27).

In-vitro dissolution test for 3 optimum formulations has shown that drug release profiles of 3 optimum formulations are similar together and 50% of drugs released in 90 seconds.

The tutti-frutti plus menthol flavor gained the best score for drug test by volunteers. Moisturizing uptake studies for 3 optimum formulations was done at 75% RH. Results indicated slight moisture uptake was seen by tablets. According to these results, special packing is needed for our ODTs. The materials with moisture stable features should be used for packing such as aluminum strip pack, aluminum blister or polyethylene sealing on blisters (23).

**CONCLUSION**

Dimenhydrinate has antimuscarinic with antihistaminic and important sedative effects. It is mostly used as an antiemetic drug in the inhibition and treatment of motion sickness. Dimenhydrinate directly prevents the stimulation of definite nerves in the brain and internal ear to suppress nausea, vomiting, dizziness, and vertigo. Dimenhydinate decrease vestibular neuronal stimulation because of angular or linear acceleration motions. This study was helping to design and formulation dimenhydrinate ODTs by effervescent and super-disintegrant bases and mixture of two bases. The results of disintegration time indicated that mixture of two bases (group 3) were better than others. F2 in group 1, F14 in group 2 and F3 in group 3 had lowest disintegration time compare other formulations in each group. OSE formulation had best disintegration time compare to all formulations.

**Conflict of Interests**

Authors have no conflict of interests.

**Acknowledgment**

This study was supported by Isfahan University of Medical Sciences as a thesis research project number 394800.

**References**

1. Sagar A, Konapure, Prafulla S. Chaudhari et al “Mouth Dissolving Tablet” An Innovative Technology. IJABPT. 2011; 2(1): 496-504.
2. Sastry SV, Nyshadham JR. Fix JA. Recent technological advances in oral drug delivery: A review. [Pharm Sci Technolo Today](https://www.ncbi.nlm.nih.gov/pubmed/10754543). 2000; 3: 45-138.
3. Ashish P, Harsoliya MS, Pathan JK, Shruti S. A review- formulation of mouth dissolving tablet. [I](http://www.ijpcs.net/)JPCS. 2011; 1(1): 1-8.
4. Dali S, Subhashis C, Sanjay S, Brahmeshwar M. Mouth Dissolving Tablets I: An Overview of Formulation Technology. Sci pharm. 2009; 77: 309–326.
5. Sudhir Bharawaj, Vinay Jain, Shailesh Sharma. R. C, Jat and Suman Jain. Orally Disintegrating Tablets: A Review. DIT. 2010; 2(1): 81-8.
6. Brown D. Orally Disintegrating Tablets-Taste over Speed. JDDST. 2003; 3: 58-61.
7. FDA/CDER. Guidance for Industry: Orally disintegrating tablets. Rockville, MD: The United States Food a Drug Administration, Center for Drug Evaluation and Research, 2008.
8. Maren P, Miriam P, Breitkreutz J. Development of Taste-Masked ordispersible Film Coating Dimenhydrinate. Pharmaceutics. 2012; 4: 551-562.
9. Halpert AG, Olmstead MC, Beninger RJ. A Review,"Mechanisms and abuse liability of the anti-histamine dimenhydrinate" .Pubmed. 2002 Jan; 26(1):61-7.
10. Yuvraj G, Upendra C, Parvin D. Estimation of dimenhydriante in bulk and pharmaceutical dosage form: method development and validation. IAJPR. 2013; 3(8): 7001-7007.
11. Heller WM. USP DI: Drug information for the health care professional. 8th ed. Rockville: The United States Pharmacopeial convention Inc. 1998; Vol IA: 327-329.
12. Hazee Peera N, Lohithasu D, Sahoo S. K, Santhosh Naidu M, Mani Kumar K, Anli Kumar V. Formulation development and evaluation of oral disintegrating tablets of zolmitriptan. Der pharmacia letter. 2013; 5(2): 324-332.
13. United States Pharmacopoeia 38-NF 33. The Official Compendia of Standards. Asian ed. Rockville, MD: United States Pharmacopoeial Convention Inc. 2015; 67, 676, 1328-1329, 3136.
14. Indian Pharmacopoeia. Vol 2. Delhi: The Controller of Publication; 1996: 735.
15. Nawale RB, Mohite KP. Formulation and evaluation of domperidone orodispersible tablet. IJPSR. 2013; 4(9): 3670-3677.
16. Lachman L, Lieberman HA, Kanig JL. The Theory and Practice of Industrial Pharmacy. 3rd ed. Philadelphia: Lea and Febiger. 1986; 183(293-300): 334–335.
17. Mahesh E, Kumar GBK, Ahmed MG, Kumar PK. Formulation and evaluation of montelukast sodium fast dissolving tablets. AJBPS. 2012; 2(14): 75-82.
18. Aslani A, Sharifian T. Formulation and evaluation of Amoxicillin effervescent tablets. Adv Biomed Res. 2014; 3: 209.
19. Saroha K, Kumar G, Paul Y. Formulation and evaluation of fast dissolving tablets of amoxicillin trihydrate using synthetic superdisintegrants. IJPSR. 2013; 4(1): 254-262.
20. Khan S, Kataria P, Nakha P, Yeole P. Taste masking of ondansetron hydrochloride by polymer carrier system and formulation of rapid-disintegrating tablets. AAPS [PharmSci](https://en.wikipedia.org/wiki/Pharmaceutical_sciences)Tech. 2007; 8: 127-133.
21. Aslani A, Fattahi F. Formulation, characterization and physicochemical evaluation of potassium citrate effervescent tablets. APB. 2013; 3(1): 217-225.
22. Thakur RR, Kashi M. An unlimited scope for novel formulations as orally disintegrating systems: Present and future prospects. JAPS. 2011; 1(1): 13-19.
23. Kolhe S, More D. Updated review on orally disintegarting tablets: Advancement in current trends. AJPT. 2013; 3(2): 45-51.
24. Bansal N, Sharma G. Formulation and evaluation of orally disintegrating tablets of ondansetron hydrochloride using natural superdisintegrants.IJPSR. 2011; 3(3): 1616-1621.
25. Nagendrakumar D, Keshavshetti GG, Pratibha. Design and evaluation of fast dissolving tablets of metoclopramide hydrochloride using synthetic and natural superdisintegrants. UJPBS. 2014; 2 (1): 16-24.
26. Parthiban KG, Kumar MP. Formulation and evaluation of oral ordispersible tablets of rizatriptan benzoate. Int J curr Pharm Res: Home. 2013; 5(3): 31-35.
27. Bhupendra GP, Bhaskar P. Formulation, evaluation and optimization of orally disintegrating tablet of piroxicam. IJPSR. 2010; 2(3): 1893-1899.

**Table 1**. Formulations designed by Design-Expert software with superdisintegrant bases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Formulations** | **SSG** **(mg)** | **CCS****(mg)** | **CP****(mg)** | **Friability****(%)** | **Disintegration time (sec)** |
| F1 | 7.50 | 7.00 | 3.00 | 0.40 | 70 |
| F2 | 7.50 | 7.00 | 7.50 | 0.36 | 16 |
| F3 | 7.50 | 3.50 | 3.00 | 0.32 | 75 |
| F4 | 12.00 | 5.25 | 7.50 | 0.38 | 19 |
| F5 | 3.00 | 7.00 | 5.25 | 0.41 | 28 |
| F6 | 12.00 | 5.25 | 3.00 | 0.35 | 72 |
| F7 | 7.50 | 5.25 | 5.25 | 0.36 | 33 |
| F8 | 3.00 | 3.50 | 5.25 | 0.32 | 44 |
| F9 | 12.00 | 7.00 | 5.00 | 0.37 | 28 |
| F10 | 3.00 | 5.25 | 3.00 | 0.33 | 68 |
| F11 | 3.00 | 5.25 | 7.50 | 0.42 | 22 |
| F12 | 7.50 | 3.50 | 7.50 | 0.41 | 24 |
| F13 | 12.00 | 3.50 | 5.25 | 0.37 | 35 |

 SSG= Sodium starch glycolate, CCS= Croscarmellose sodium, CP= Crospovidone

**Table 2**. Formulations designed by Design-Expert software with effervescent bases

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Formulations** | **Citric acid****(mg)** | **Na bicarbonate (mg)** | **Friability****(%)** | **Disintegration time (sec)** |
| F14 | 27.00 | 24.00 | 0.40 | 49 |
| F15 | 9.00 | 24.00 | 0.31 | 72 |
| F16 | 18.00 | 24.00 | 0.36 | 61 |
| F17 | 9.00 | 35.00 | 0.32 | 69 |
| F18 | 18.00 | 13.00 | 0.33 | 77 |
| F19 | 18.00 | 35.00 | 0.33 | 58 |
| F20 | 9.00 | 13.00 | 0.31 | 75 |
| F21 | 27.00 | 13.00 | 0.37 | 64 |
| F22 | 27.00 | 35.00 | 0.42 | 47 |

**Table 3**. Formulations designed by Design-Expert software with superdisintegrant and effervescent bases

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Formulations** | **Citric acid****(mg)** | **Na bicarbonate****(mg)** | **CP****(mg)** | **Friability****(%)** | **Disintegration time (sec)** |
| F23 | 24.00 | 48 | 4.00 | 0.36 | 32 |
| F24 | 24.00 | 48 | 7.00 | 0.37 | 21 |
| F25 | 36.00 | 48 | 4.00 | 0.39 | 25 |
| F26 | 12.00 | 48 | 10.00 | 0.38 | 22 |
| F27 | 12.00 | 48 | 7.00 | 0.36 | 28 |
| F28 | 36.00 | 48 | 7.00 | 0.39 | 21 |
| F29 | 24.00 | 48 | 10.00 | 0.40 | 18 |
| F30 | 36.00 | 48 | 10.00 | 0.41 | 12 |
| F31 | 12.00 | 48 | 4.00 | 0.36 | 35 |

 CP= Crospovidone

**Table 4**. Ingredients for dimenhydrinate ODTs with superdisintegrant bases

|  |  |
| --- | --- |
| **Ingredients****(mg)** | **Formulations** |
| **F1** | **F2** | **F3** | **F4** | **F5** | **F6** | **F7** | **F8** | **F9** | **F10** | **F11** | **F12** | **F13** |
| Dimenhyrinate | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
| SSG | 3 | 3 | 3 | 3 | 7.5 | 7.5 | 7.5 | 7.5 | 7.5 | 12 | 12 | 12 | 12 |
| CCS | 7 | 3.5 | 5.25 | 5.25 | 7 | 7 | 3.5 | 5.25 | 3.5 | 5.25 | 5.25 | 7 | 3.5 |
| CP | 5.25 | 5.25 | 3 | 7.5 | 3 | 7.5 | 3 | 5.25 | 7.5 | 7.5 | 3 | 5.25 | 5.25 |
| MCC | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 | 30 |
| Sucralose | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Mannitol | 72.75 | 76.25 | 76.75 | 72.25 | 70.5 | 66 | 74 | 70 | 69.5 | 63.25 | 67.75 | 63.75 | 65 |
| Mg stearate | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Total weight | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 |

 SSG= Sodium starch glycolate, CCS= Croscarmellose sodium, CP= Crospovidone

 MCC= Microcrystalline cellulose

**Table 5**. Ingredients for dimenhydrinate ODTs with effervescent bases

|  |  |
| --- | --- |
| **Formulations** | **Ingredients****(mg)** |
| **F22** | **F21** | **F20** | **F19** | **F18** | **F17** | **F16** | **F15** | **F14** |
| 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | Dimenhydrinate |
| 27 | 27 | 27 | 18 | 18 | 18 | 9 | 9 | 9 | Citric acid |
| 35 | 24 | 13 | 35 | 24 | 13 | 35 | 24 | 13 | Na bicarbonate |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | Sucralose |
| 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | PEG6000 |
| 54 | 65 | 76 | 63 | 74 | 85 | 72 | 83 | 94 | Mannitol |
| 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | Total weight |

**Table 6**. Ingredients for dimenhydrinate ODTs with superdisintegrant and effervescent bases

|  |  |
| --- | --- |
| **Formulations** | **Ingredients****(mg)** |
| **F31** | **F30** | **F29** | **F28** | **F27** | **F26** | **F25** | **F24** | **F23** |
| 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | Dimenhydrinate |
| 36 | 36 | 36 | 24 | 24 | 24 | 12 | 12 | 12 | Citric acid |
| 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | Na bicarbonate |
| 10 | 7 | 4 | 10 | 7 | 4 | 10 | 7 | 4 | CP |
| 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | Sucralose |
| 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | 40 | MCC |
| 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | 4.6 | PEG6000 |
| 41.4 | 44.4 | 47.4 | 53.4 | 56.4 | 59.4 | 65.4 | 68.4 | 71.4 | Mannitol |
| 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | Mg stearate |
| 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | Total weight |

 CP= Crospovidone, MCC= Microcrystalline cellulose

 **Table** **7**. Optimum formulations that proposed by Design-Expert software

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Disintegration time (sec) | Friability(%) | CA(mg) | SB(mg) | SSG(mg) | CCS(mg) | CP(mg) | **Formulations** |
| O | E | O | E |
| 17.36 | 16.97 | 0.38 | 0.39 |  |  | 4.84 | 6.74 | 7.09 | OS |
| 46.21 | 47.90 | 0.39 | 0.39 | 26.52 | 34.70 |  |  |  | OE |
| 12.35 | 11.89 | 0.37 | 0.38 | 30.96 | 36 |  |  | 9.97 | OSE |

 SSG= Sodium starch glycolate, CCS= Croscarmellose sodium, CP= Crospovidone

 SB= Na bicarbonate, CA= Citric acid, E= Estimated, O= Obtained

 OS= Optimum Superdisintegrant formulation, OE= Optimum Effervescent formulation

 OSE= Optimum Superdisintegrant and Effervescent formulation

 **Table** **8**. Evaluation of physicochemical characteristics of mixed powders

|  |  |
| --- | --- |
|  **Physicochemical properties (mean ±SD)**  | **Formulations** |
| **Compressibility index (%)** | **Husner's ratio** | **Angle of repose** | **Tapped density(g/cm3)** | **Bulk density****(g/cm3)** |
| 5.02±0.21 | 1.12±0.02 | 24.67±0.91 | 0.66±0.03 | 0.59±0.03 | F1 |
| 7.34±0.12 | 1.01±0.01 | 26.54±1.16 | 0.65±0.08 | 0.64±0.02 | F2 |
| 6.89±0.18 | 1.10±0.01 | 25.52±0.88 | 0.67±0.04 | 0.61±0.02 | F3 |
| 8.35±0.16 | 1.12±0.04 | 28.36±0.98 | 0.65±0.02 | 0.58±0.03 | F4 |
| 6.05±0.13 | 1.13±0.02 | 25.89±1.01 | 0.68±0.06 | 0.60±0.01 | F5 |
| 7.76±0.23 | 1.06±0.03 | 27.33±0.93 | 0.67±0.01 | 0.63±0.04 | F6 |
| 8.32±0.14 | 1.05±0.06 | 26.96±1.08 | 0.65±0.04 | 0.62±0.07 | F7 |
| 4.97±0.19 | 1.03±0.03 | 25.09±0.90 | 0.66±0.02 | 0.64±0.04 | F8 |
| 5.68±0.10 | 1.10±0.05 | 26.22±1.13 | 0.68±0.07 | 0.62±0.02 | F9 |
| 9.01±0.27 | 1.01±0.02 | 28.98±0.98 | 0.66±0.09 | 0.65±0.03 | F10 |
| 8.87±012 | 1.10±0.07 | 26.39±1.09 | 0.65±0.03 | 0.59±0.08 | F11 |
| 7.56±0.16 | 1.06±0.08 | 27.69±1.12 | 0.68±0.05 | 0.64±0.07 | F12 |
| 5.97±0.20 | 1.06±0.02 | 29.01±1.15 | 0.66±0.07 | 0.62±0.05 | F13 |
| 8.34±0.19 | 1.04±0.04 | 28.69±0.99 | 0.69±0.09 | 0.66±0.04 | F14 |
| 6.64±0.14 | 1.06±0.03 | 26.48±1.08 | 0.66±0.02 | 0.62±0.02 | F15 |
| 5.83±0.15 | 1.08±0.06 | 27.99±0.95 | 0.68±0.04 | 0.63±0.06 | F16 |
| 8.84±0.17 | 1.10±0.04 | 25.47±1.19 | 0.65±0.07 | 0.59±0.08 | F17 |
| 5.76±0.23 | 1.08±0.03 | 26.64±1.14 | 0.68±0.04 | 0.63±0.02 | F18 |
| 5.03±0.12 | 1.06±0.06 | 28.54±0.98 | 0.65±0.07 | 0.61±0.06 | F19 |
| 5.93±0.13 | 1.06±0.02 | 27.08±1.02 | 0.67±0.05 | 0.63±0.03 | F20 |
| 8.91±0.16 | 1.06±0.8 | 28.37±0.93 | 0.66±0.03 | 0.62±0.02 | F21 |
| 7.98±0.18 | 1.10±0.01 | 26.78±0.93 | 0.64±0.04 | 0.58±0.08 | F22 |
| 5.74±0.28 | 1.10±0.05 | 28.39±1.20 | 0.68±0.08 | 0.62±0.04 | F23 |
| 6.99±0.12 | 1.03±0.03 | 28.91±0.92 | 0.67±0.05 | 0.65±0.03 | F24 |
| 7.82±0.08 | 1.06±0.09 | 24.65±1.02 | 0.66±0.07 | 0.62±0.04 | F25 |
| 6.68±0.13 | 1.10±0.02 | 25.63±0.94 | 0.68±0.04 | 0.62±0.05 | F26 |
| 7.14±0.07 | 1.08±0.04 | 24.96±1.08 | 0.69±0.01 | 0.64±0.05 | F27 |
| 8.13±0.21 | 1.02±0.03 | 26.04±1.23 | 0.64±0.06 | 0.63±0.03 | F28 |
| 6.48±0.12 | 1.11±0.06 | 29.08±1.06 | 0.68±0.04 | 0.61±0.02 | F29 |
| 7.56±0.19 | 1.08±0.02 | 27.64±0.96 | 0.67±0.07 | 0.62±0.06 | F30 |
| 6.05±0.19 | 1.08±0.09 | 25.13±1.21 | 0.65±0.02 | 0.60±0.01 | F31 |
| 6.32±0.41 | 1.08±0.03 | 26.17±1.32 | 0.64±0.09 |  0.59±0.06 | OS |
| 8.16±0.36 | 1.11±0.08 | 27.75±1.09 | 0.68±0.06 | 0.61±0.04 | OE |
| 7.93±0.25 | 1.03±0.02 | 26.87±1.18 | 0.69±0.12 | 0.67±0.10 | OSE |

 OS= Optimum Superdisintegrant formulation, OE= Optimum Effervescent formulation

 OSE= Optimum Superdisintegrant and Effervescent formulation

**Table** **9**. Physicochemical properties of the optimum ODTs prepared by direct compression method (Mean ± SD)

|  |  |
| --- | --- |
| **Physicochemical properties (mean ±SD)** | **Formulations** |
| Wetting time(sec) | Water content (%) | Content uniformity (%) | Assay(mg) | Weight variation (mg) | Hardness (N) | Thickness (mm) |
| 22±0.87 | 0.29±0.11 | 98.75±1.25 | 24.86±1.21 | 148.0±1.69 | 38.03±1.97 | 3.36±0.06 | OS |
| 37±0.98 | 0.45±0.19 | 96.44±1.67 | 25.06±1.53 | 150.9±1.36 | 33.25±2.36 | 3.44±0.08 | OE |
| 19±1.13 | 0.36±0.23 | 99.02±1.94 | 24.93±1.12 | 198.86±1.73 | 36.23±1.35 | 3.84±0.16 | OSE |

OS= Optimum Superdisintegrant formulation, OE= Optimum Effervescent formulation

OSE= Optimum Superdisintegrant and Effervescent formulation

Figure 1. In vitro dissolution test for optimum ODTs in purified water 37±0.5°C